China plant expansion bites ShangPharma; UCB selling Indian plant; India mulls new EU API rule;

> Belgium-based UCB is selling a plant in Vapi, India, to Indian API maker Exemed Pharmaceuticals for an undisclosed amount. Story

> The Pharmaceuticals Export Promotion Council of India (Pharmexcil) said while it is considering how to address the 2013 requirement by the EU that all APIs must come from plants that the home country has inspected and certified, the government has yet to finalize how that will be accomplished. Item

> Chinese CRO ShangPharma blamed a nearly 40% drop in net income on the cost of new plants, many of which are yet to come online and start generating revenue, including a new manufacturing plant in Fengxian, China. Story

> German CureVac has developed an RNA vaccine that can be used to manufacture a flu vaccine faster than egg-derived vaccine and will not require cold-chain delivery. Story

> Two class 10,000 clean room facilities are part of the manufacturing upgrades made by Israel's Immunovative Therapies in anticipation of more demand. Item

And Finally... Schott Pharmaceutical Packaging says it will bump up capacity at its plant in Zavolzhe, Russia, by more than 50%. Item

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.